**Facebook****Email**Print**Facebook****Email

## Overview

#### Associate Scientist

Massimo Gadina, Ph.D.

Massimo.gadina@nih.gov

The development of accurate and reproducible immune monitoring assays is essential to determine the immune responses in patients receiving novel immune therapies and ultimately transitioning these therapies from the clinical trial phase to standard of care. The goal of the Translational Immunology Section (TIS) is to develop cutting-edge immune monitoring technology that will be made available to all NIAMS investigators.

The Translational Immunology Section supports NIAMS scientists with:
                          - Consultative advice and in-depth instructions in a variety of immunologic methods to facilitate their interpretation of immunoassays most relevant to a particular clinical trial or to study a particular patient.
                          - State-of-the-art immunoassays such as high parameters, multicolor flow cytometry, Luminex, and NanoString transcriptomic analysis enabling NIAMS clinicians to monitor the immune responses of their patients.
                          - Analysis of a reference population to define baseline responses, ensuring quality control checks that will validate the reproducibility of these results.
                          - Analysis of the mechanism of action of JAK inhibitors on various immune cell populations.

#### Scientific Advances

October 3, 2023

The Transcription Factor STAT4 Controls the Fate of Cytotoxic Innate Lymphocytes

#### In the Lab with NIAMS

Learn more about the NIAMS Translational Immunology Section, a Core Facility in the institute’s Intramural Research Program. This facility uses genomic approaches to understand the underlying factors of human diseases.

#### Core Research Facilities

Labs at the NIAMS are supported by the following state-of-the-art facilities and services:
                                        - Biodata Mining and Discovery
                                        - Flow Cytometry
                                        - Genomic Technology
                                        - Laboratory Animal Care and Use
                                        - Light Imaging
                                        - Translational Immunology

## Staff

**Massimo Gadina, Ph.D.**

Massimo.gadina@nih.gov

**Sabrina Helmold Hait, Ph.D.**

helmoldhaits@nih.gov

**Shajia Lu **

lushajia@mail.nih.gov 

**Mary Maclean, Ph.D.**

mary.maclean@nih.gov

**Cindy Phung, B.S.**

cindy.phung@nih.gov

**Wanxia Li Tsai, M.S.**

liwan@mail.nih.gov

## Scientific Publications

## Selected Recent Publications

###             Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.        

83(2).

###             Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome.        

388(24).

###             Protein kinases: drug targets for immunological disorders.        

23(12).

###             Cell Viability Multiplexing: Quantification of Cellular Viability by Barcode Flow Cytometry and Computational Analysis.        

2644().

###             PDIA3 epitope-driven immune autoreactivity contributes to hepatic damage in type 2 diabetes.        

7(74).

###             The JAK-STAT pathway at 30: Much learned, much more to do.        

185(21).

###             Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis.        

18(3).

###             Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies.        

15(1).

###             Granzyme A and CD160 expression delineates ILC1 with graded functions in the mouse liver.        

51(11).

###             3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine.        

12(1).

###             A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?        

73(12).

###             Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.        

12(1).

###             JAK1: Number one in the family; number one in inflammation?        

60(Suppl 2).

###             Pleiotropic consequences of metabolic stress for the major histocompatibility complex class II molecule antigen processing and presentation machinery.        

54(4).

###             Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.        

80(3).

## Key Publications

###                 JAK inhibitors: Ten years after.            

###                 Somatic Mutations in *UBA1* and Severe Adult-Onset Autoinflammatory Disease.            

383(27).

###                 HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.            

5(47).

###                 JAK Inhibition Differentially Affects NK Cell and ILC1 Homeostasis.            

10().

###                 High throughput pSTAT signaling profiling by fluorescent cell barcoding and computational analysis.            

477().

See all Publications on PubMed

## News & Highlights

**Facebook****Email**Print**Facebook****Email